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Abstract: Vitiligo is an acquired cutaneous disorder of pigmentation, with an incidence of  0.5% 
to 2% worldwide. There are three major hypotheses for the pathogenesis of vitiligo that are not 
exclusive of each other: biochemical/cytotoxic, neural and autoimmune. Recent data provide 
strong evidence supporting an autoimmune pathogenesis of vitiligo. As vitiligo can have a major 
effect on quality of life, treatment can be considered and should preferably begin early when the 
disease is active. Current treatment modalities are directed towards stopping progression of the 
disease and achieving repigmentation. Therapies include corticosteroids, topical immunomodu-
lators, photo(chemo)therapy, surgery, combination therapies and depigmentation of normally 
pigmented skin. Topical class 3 corticosteroids can be used for localized vitiligo. The use of 
topical immunomodulators (TIMs) in vitiligo seems to be equally effective as topical steroids, 
especially when used in the face and neck region. In photo(chemo)therapy, narrowband ultra-
violet-B therapy (NB-UVB) seems to be superior to psoralen ultraviolet-A therapy (PUVA) and 
broadband UVB. In surgical techniques, split-thickness grafting and epidermal blister grafting 
were shown to be effective methods, although the non-cultured epidermal suspension technique 
has many advantages and seems to be a promising development. Depigmentation therapy can 
be considered if vitiligo affects more than 60% to 80% of the body. Complementary therapies 
such as Polypodium leucotomos show promising results in combination with UVB therapy. 
No causative treatment for vitiligo is currently available. More randomized controlled trials on 
the treatment of vitiligo are necessary.
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Introduction
Vitiligo is an acquired cutaneous disorder of pigmentation, with a 0.5% to 2% incidence 
worldwide, without predilection for sex or race. Besides skin, oral mucosa and hair 
may also be depigmented. Classically, vitiligo is divided into segmental and general-
ized forms. The age of onset of vitiligo is variable, but peaks in the second and third 
decades. The depigmentation has a predilection for acral areas and around body oriﬁ  ces 
(mouth, eyes, nose, anogenital region).1
The Vitiligo European Task Force (VETF) was founded in 2003 during the ESPCR 
meeting in Ghent and formulated the following deﬁ  nition:
“Generalized vitiligo or non-segmental vitiligo (NSV) is an acquired chronic pig-
mentation disorder characterized by white patches, often symmetrical, which usually 
increase in size with time, corresponding to a substantial loss of functioning epidermal 
and sometimes hair follicle melanocytes”.2
“Segmental vitiligo is an acquired chronic pigmentation disorder characterized 
by white patches with a unilateral distribution that may totally or partially match 
a dermatome, but not necessarily. Other distribution patterns can be encountered 
that cross several dermatomes, or correspond to large areas delineated by Blaschko’s 
lines”.2Clinical, Cosmetic and Investigational Dermatology 2009:2 16
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Pathogenesis
The precise cause of vitiligo is unknown. There are 3 major 
hypotheses for the pathogenesis of vitiligo that are not 
exclusive of each other: biochemical/cytotoxic, neural and 
autoimmune. The autoimmune hypothesis is based on genetic 
data and the fact that vitiligo is associated with other auto-
immune diseases. The cytotoxic theory postulates that cell 
death of melanocytes is caused by cytotoxic precursors to 
melanin synthesis. The neural hypothesis is based on case 
reports were patients with nerve injury develop vitiligo at 
the affected sites and links segmental vitiligo with neurons 
that interact with melanocytes and release melanocytotoxic 
substrates.3
As none of the three hypotheses is sufﬁ  cient to explain 
fully the mechanisms of vitiligo, the convergence theory 
is proposed. This theory states that stress, accumulation of 
toxic compounds, infection, autoimmunity, mutations, altered 
cellular environment and impaired melanocyte migration and 
proliferation can all contribute in varying proportions to the 
etiopathogenesis of vitiligo.4
There is increasing evidence for an autoimmune patho-
genesis of vitiligo. In 2000, van den Wijngaard et al analyzed 
lesional, perilesional, and non-lesional skin biopsies from 
patients with vitiligo and compared these with immune inﬁ  l-
trates found in the skin of normal healthy donors and relevant 
disease controls and found a major role for skin-homing 
T cells in the death of melanocytes seen in vitiligo.5
An autoimmune process is also suggested by the con-
comitant occurrence of other autoimmune diseases like 
autoimmune thyroiditis, diabetes mellitus, pernicious ane-
mia, Addison’s disease, primary adrenal insufﬁ  ciency and 
hypopituitarism in patients with vitiligo.6
Genetic factors also appear to play a role in the etio-
pathogenesis of vitiligo as 20% to 30% of patients have 
a family history of the disorder.7 Vitiligo does not follow 
a normal Mendelian pattern of inheritance, and it has been 
suggested that the disease most likely has a multifactorial, 
polygenic basis.8
However, many patients with vitiligo have neither 
a family history of vitiligo nor a history of other autoimmune 
diseases. A number of other hypotheses have been proposed 
to explain the pathogenesis of this disorder, like an intrinsic 
abnormality of melanocytes, increased local catecholamine 
release, hypoxia, oxidative stress and melanocytorrhagia.9
Treatment
Since a causative treatment is not available, current treatment 
modalities are directed towards stopping the progression of 
vitiligo and achieving repigmentation in order to repair the 
morphology and functional deﬁ  ciencies of the depigmented 
skin areas.10 Current treatment modalities aim to stimulate 
melanocyte proliferation or interfere with inﬂ  ammatory 
factors affecting melanocyte structure or function. No single 
treatment method has yet been found that is consistently 
effective with relatively few side-effects.11
Current repigmentation therapies include corticosteroids, 
topical immunomodulators, photo(chemo)therapy, surgery 
and depigmentation of normally pigmented skin.
Non-surgical repigmentation treatment
Corticosteroids
Different classes of topical corticosteroids were studied. Topical 
steroids are most effective for lesions on the face, elbows and 
knees, the distal extremities respond poorly. Factors contrib-
uting to the variation in repigmentation rate by anatomic site 
include skin permeability, migration of residual melanocytes 
from uninvolved skin, reversibility of melanocyte damage and 
especially preservation and density of follicular reservoirs.13
In 1977, Bleehen performed a placebo controlled study 
and treated 20 patients with vitiligo either with 0.1% beta-
methasone valerate or with 0.05% clobetasol propionate 
creams and similar control areas with placebo preparations 
and concluded that both topical corticosteroids could be 
used for the treatment of selected patients with vitiligo and 
can induce repigmentation of the skin.14 Clayton conducted 
a double blind study and compared 0,05% clobetasol propri-
onate in a cream base with the cream base alone and came to 
the conclusion that the active product was signiﬁ  cantly supe-
rior to the cream base alone in the treatment of vitiligo.15
In a controlled randomized trial by Kandil, 0.1% beta-
methasone valerate in 50% isopropyl alcohol was compared 
to the alcohol base alone in 19 patients with vitiligo. A higher 
percentage of lesions had complete repigmentation when 
treated with the active product as compared to placebo.16
A study by Lepe et al compared (left-right) 0.05% clo-
betasol proprionate with 0.1% tacrolimus for the treatment 
of vitiligo in children and showed a similar repigmentation 
rate of 49.3% for clobetasol and 41.3% for tacrolimus.17 
Sanclemente et al compared the effect of topical 0.05% 
betamethasone valerate versus catalase/dismutase superoxide 
(C/DSO) in a randomized, matched-paired, double-blind trial 
with 25 patients and concluded that vitiligo repigmentation 
with topical C/DSO at 10 months is similar to repigmenta-
tion with topical 0.05% betamethasone valerate.18
In 1999, Njoo et al performed a meta-analysis of 20 ran-
domized controlled trials and 75 patient series on the treatment Clinical, Cosmetic and Investigational Dermatology 2009:2 17
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of vitiligo and concluded that topical class 3 corticosteroids 
and ultraviolet-B therapy (UVB therapy) are the most effec-
tive and safest therapies for localized and for generalized 
vitiligo, respectively.19
The biggest side-effect of topical corticosteroids is skin 
atrophy, more seen in class 4 than in class 3 corticosteroids. 
Other side-effects were striae, hypertrichosis, acneiform 
eruption and telangiectasia.
High and low doses of oral corticosteroids in pulse 
therapy have been shown to be successful in patients with 
progressive disease.20,21 Recently, Rath et al compared dif-
ferent phototherapy methods (psoralen ultraviolet-A PUVA 
[therapy], narrowband UVB and broadband UVB) with an 
oral minipulse of steroids (OMP) as an adjunct to determine 
the method with the best tolerability and efﬁ  cacy. They ran-
domly assigned 68 patients with progressive vitiligo to differ-
ent study groups (OMP, OMP + PUVA, OMP + narrowband 
UVB, OMP + broadband UVB). Each patient was followed 
up for 6 months and then the treatment was discontinued. 
Clinical evaluation was made at the end of 3 and 6 months. 
They concluded that the oral steroids only had an adjunct 
value and were not very effective by themselves. Narrowband 
UVB is preferred over broadband UVB. Narrowband UVB 
and PUVA showed comparable efﬁ  cacy.22
No placebo controlled studies have been performed for the 
use of oral corticosteroids in vitiligo yet. So their use is still 
considered controversial since systemic side-effects (eg, moon 
face, weight gain) are associated with this therapy.
Photo(chemo)therapy
The ultraviolet (UV)-spectrum is divided into 3 major groups: 
UVA, UVB en UVC. UVC-radiation (200–280 nm) is ﬁ  ltered 
by the atmosphere and has no place in phototherapy. UVB-
radiation (280–320 nm) is biologically the most active. 
UVA-radiation (320–400 nm) has the longest wavelength of 
the UV-spectrum and is biologically less active than UVB-
radiation. However, it is partly responsible for erythema and 
pigmentation induced by sunlight.23
(P)UVA
Only a few studies (no randomized, controlled trials) have 
been performed, studying UVA-therapy in vitiligo. El Mofty 
et al studied the effect of broadband UVA on vitiligo lesions 
in 20 patients, 15 J/cm2 in group I and 5 J/cm2 in group II, 
a total of 48 sessions over 16 weeks. All patients received 
3-weekly sessions of UVA. Overall pigmentation of 60% and 
above was recorded in 50% and 10% of patients in groups I 
and II, respectively. They concluded that broadband UVA 
alone, without psoralens, may have an important therapeutic 
value in the treatment of vitiligo.24
Westerhof et al performed a left-right comparison study 
of the combination of ﬂ  uticasone propionate and UVA versus 
either ﬂ  uticasone propionate or UVA for the long-term treat-
ment of vitiligo and concluded that the combination treatment 
with ﬂ  uticasone proprionate and UVA is much more effective 
in reaching complete repigmentation than are ﬂ  uticasone 
proprionate and UVA used alone, but large inter-individual 
differences occurred in the study.25
PUVA therapy
This is the combination of body irradiation with UVA-light 
and a psoralenderivate. The psoralens most commonly 
used are 8-methoxypsoralen (8-MOP), 5-methoxypsoralen 
(5-MOP) and 4,5’, 8-trimethylpsoralen (TMP). Already in 
ancient Egyptian times, plant extracts containing psoralens 
were used to treat patients with vitiligo.26 In the 1940’s, 
PUVA was introduced to treat vitiligo.27 In PUVA therapy, 
the psoralens can be applied topically or can be taken orally. 
In vitro studies demonstrated that oral PUVA stimulates 
melanocytes to proliferate, differentiate and migrate. It 
also has a local immunomodulatory effect.28 Ermis et al 
performed a placebo-controlled double-blind study to inves-
tigate whether the effectiveness of PUVA therapy could be 
enhanced by combination with topical calcipotriol in the 
treatment of vitiligo and concluded that concurrent topical 
calcipotriol potentiates the efﬁ  cacy of PUVA therapy in the 
treatment of vitiligo, and that this combination achieves 
earlier pigmentation with a lower total UVA dosage.29
Oral PUVA therapy has a lot of side-effects like nausea, 
pruritus, phototoxic reactions and a large contrast in pig-
mentation between normal and repigmented skin. Therefore, 
PUVA therapy is not the ﬁ  rst choice in the treatment of 
vitiligo.
UVB
The exact mechanism of vitiligo repigmentation due to UVB 
is not known. It is probably related to the positive effect of 
UVB on immunomodulation, growth stimulation and pro-
liferation of melanocytes.
The traditional broadband UVB sources were the ﬁ  rst to 
be used. Broadband UVB therapy, which implies signiﬁ  cant 
exposure to wavelength spectra of less than 300 nm and even 
less than 280 nm (UVC), carries in theory a greater risk of 
long-term development of nonmelanoma skin cancer com-
pared with narrowband UVB (UVB 311 nm), although there 
is no clinical study that proves this in practice.30Clinical, Cosmetic and Investigational Dermatology 2009:2 18
Borderé et al
In 1990, Köster et al reported repigmentation of more 
than 75% in 8 of 14 patients suffering from extensive vitiligo, 
who underwent phototherapy with broadband UVB. Espe-
cially the patients with facial lesions of the skin types V and 
VI achieved a nearly complete and cosmetically satisfying 
repigmentation after 12 months of treatment.31
Recently, Asawanonda et al performed a small ran-
domized, controlled trial (20 patients) comparing targeted 
narrowband UVB with targeted broadband UVB and 
concluded that the clinical responses were similar in both 
groups. However, the device used in this trial was a targeted 
UVB device, this implicates that the results cannot be applied 
to other light sources (eg, excimer laser or total-body irradia-
tion cabinets).32
Narrowband UVB (NB-UVB) is a more recent form 
of phototherapy that uses wavelengths between 305 and 
311 nm. Short-time side-effects include pruritus and xerosis, 
long-term side-effects (eg, carcinogenesis) are unknown. 
NB-UVB can be used in children, pregnant or lactat-
ing women and in individuals with hepatic or kidney 
dysfunction.23
In 1997, Westerhof ﬁ  rst reported the use of NB-UVB 
phototherapy for the treatment of vitiligo and concluded 
the treatment of patients with vitiligo with 311-nm UV-B 
radiation is as efﬁ  cient as with topical PUVA and has fewer 
adverse effects.33 In a recent study by Rath et al narrowband 
UVB was preferred over broadband UVB. Narrowband UVB 
and PUVA showed comparable efﬁ  cacy.22
Esfandiarpour et al studied 68 patients with vitiligo. 
The patients were divided into two groups and treated 
with NB-UVB in combination with pimecrolimus or with 
NB-UVB in combination with a placebo cream for 3 months. 
The authors concluded that, on the face, NB-UVB works 
better if combined with 1% pimecrolimus cream rather than 
used alone.34
El Mofty et al performed an evaluation of NB-UVB 
311 nm in the treatment of vitiligo by two independent 
studies. The ﬁ  rst study compared NB-UVB with PUVA 
therapy, and the second study compared NB-UVB with 
NB-UVB + psoralens. They showed no statistical differ-
ence in repigmentation or side-effects between NB-UVB 
and PUVA therapy. In the second study, there was no 
statistical difference in repigmentation between NB-UVB 
and NB-UVB + psoralens, but the group with psoralens had 
more side- effects.35
In 2007, Yones et al performed a randomized double blind 
trial in 56 patients with nonsegmental vitiligo, comparing 
PUVA therapy with NB-UVB therapy and concluded that, 
in the treatment of nonsegmental vitiligo, NB-UVB therapy 
is superior to oral PUVA therapy.36
Arca et al compared NB-UVB as monotherapy to the 
combination of NB-UVB + calcipotriol in a randomized 
study and concluded that NB-UVB is an effective therapy 
for vitiligo but they could not show an additional effect of 
topical calcipotriol.37
We can conclude that narrowband UVB is as effective 
(or more effective) than PUVA therapy in the treatment of 
vitiligo but has fewer side-effects. It is preferred over broad-
band UVB and is a promising treatment for vitiligo.
Excimer laser
The xenon chloride excimer laser emits a wavelength of 
308 nm. The excimer laser has some useful technical char-
acteristics like an articulated arm and variable spot size. It 
is possible to selectively turn the beam of light and to treat 
only the involved area, sparing healthy skin. In vitiligo, this 
selectivity limits the unwanted hyperpigmentation of non 
involved skin, which is commonly observed with the other 
phototherapies. The articulated arm makes it possible to treat 
body regions that are otherwise difﬁ  cult to reach (eg, folds 
and mucosa). Disadvantages include the fact that the limited 
spot size means that large surfaces (20% of total surface 
body area) cannot be treated and that purchase and mainte-
nance costs of these devices remain quite expensive.38
Hadi et al performed a retrospective chart review of 
97 patients (a total of 221 vitiligo patches) with chronic stable 
vitiligo treated with the excimer laser and concluded that it is 
an effective and safe modality for the treatment of vitiligo, with 
good results achieved in a relatively short duration of time. 
Lesions on the face responded better than lesions elsewhere.39
In 2006, Passeron and Ortonne performed a review of 
10 studies on the use of the 308-nm excimer laser for pso-
riasis and vitiligo. For vitiligo, low ﬂ  uencies (from 50 to 
200 mJ/cm2) were used in 1 to 3 sessions a week for 1 to 
6 months, depending on the study. The number of plaques 
with repigmentation at the end of the treatment was high 
(57%–100%). On average, 20% to 30% of treated plaques 
reach more than 75% repigmentation, but some series report 
conﬂ  icting results (from 0% to 75%). The clinical response 
to the treatment is especially dependent of the localization 
of the lesions. UV-resistant areas (eg, extremities and bony 
prominences) were more difﬁ  cult to treat.38
Passeron et al examined the efﬁ  cacy of combined treat-
ment with 0.1% tacrolimus ointment plus 308 nm excimer 
laser versus excimer laser monotherapy. They concluded that 
the combined therapy was only superior to the excimer laser Clinical, Cosmetic and Investigational Dermatology 2009:2 19
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monotherapy for the treatment of UV-resistant vitiliginous 
lesions.40
Goldinger et al did a prospective (left-right) comparative, 
single blinded study to compare the effectiveness of the 
excimer laser and the combination of the excimer laser with 
topical calcipotriol in the treatment of vitiligo. They showed 
no signiﬁ  cant difference in overall repigmentation between 
the two groups.41
Just recently, Sassi et al did a randomized, controlled 
trial to compare the effectiveness of the 308 nm excimer 
laser alone or in combination with topical hydrocortisone 
17-butyrate cream in patients with vitiligo, unresponsive to 
previous treatment with topical steroids or narrowband ultra-
violet B phototherapy. They found that recalcitrant vitiligo 
of the face and neck may beneﬁ  t from the combination of 
excimer laser phototherapy with topical hydrocortisone 
17-butyrate cream.42
The excimer laser is a promising therapy for vitiligo, with 
good clinical results, especially for the treatment of vitiligo 
lesions on the face.
Calcipotriol
Calcipotriol is a vitamin D3 analogue that might be effective 
on immunomodulatory systems, inﬂ  ammatory mediators and 
melanocytes.43 Tomita et al showed that vitamin D3 induced 
features similar to those noted in UV-radiated skin (such 
as swelling of melanocytes in the epidermis and increased 
tyrosinase activity resulting in a deposition of melanin in 
the epidermis).44
Kumaran et al conducted a randomized trial that studied 
the effect of 0,005% topical calcipotriol, 0.05% betametha-
sone dipropionate and their combination in the treatment of 
localized vitiligo. When used individually, the betamethasone 
dipropionate and the calcipotriol were found to be equally 
effective but the combination of the two appeared to give 
a signiﬁ  cantly faster onset of repigmentation along with 
better stability of the achieved pigmentation and with lesser 
number of side-effects.45
Ameen et al conducted an open study to investigate 
the efﬁ  cacy and tolerability of calcipotriol cream as mono-
therapy and in combination with PUVA therapy. They 
found that topical calcipotriol appears to be an effective and 
well-tolerated treatment for vitiligo and can be safely used 
in combination with PUVA.46 Chiavérini et al performed a 
prospective, right-left comparative, open study and exam-
ined the efﬁ  ciency of topical calcipotriol as a monotherapy 
for the treatment of vitiligo. They concluded that it was not 
effective.47
However, no randomized controlled trials have been 
performed yet with calcipotriol as a monotherapy for vitiligo. 
The combination of calcipotriol and PUVA or UVB has also 
been studied in other trials, but the results are contradicting 
as some authors describe a beneﬁ  t as others do not.41,43
Topical immunomodulators (tacrolimus/
pimecrolimus)
Tacrolimus and pimecrolimus (macrolide immunomodulators) 
can be used topically and are called topical immunomodu-
lators (TIMs). TIMs inhibit the action of calcineurin, and 
consequently prevent the transcription of inﬂ  ammatory 
cytokines dependent on the transcription factor nuclear fac-
tor of activated T-cells (NF-AT). This reversible inhibition 
of cytokine synthesis affects both T helper type 1 (Th-1) 
cytokines (interleukin-2, interferon-γ) and Th-2 cytokines 
(interleukin-4, interleukin-10). This is considered the work-
ing mechanism of action of TIMs in vitiligo.48,49
The use of TIMs in vitiligo has been documented in 
randomized controlled trials and in several case reports and 
open studies. One randomized controlled study compared 
0.1% tacrolimus and 0.05% clobetasol cream in 20 children 
with vitiligo. The level of repigmentation was 49.3% with 
clobetasol and 41.3% with tacrolimus.17 Dawid et al per-
formed a double-blind, intra-patient comparison of 1% 
pimecrolimus cream with placebo cream in 20 patients with 
vitiligo predominantly situated on the extremities and not 
on the face and found no signiﬁ  cant change in mean target 
lesion.49
Since 2002, clinical studies have favored the use of calci-
neurin inhibitors in vitiligo, especially in children, in whom 
they were shown to be equally effective as corticosteroids. 
However, in adult patients the effect was mainly restricted 
to the face and neck, whereas lesions in other regions of the 
body showed variable responses.50 Just recently, Choi et al 
performed a retrospective review of 79 patients and showed 
that topical immunomodulators are as effective as topical 
steroids in repigmentation of vitiligo. They also showed 
that the duration between start of treatment and onset of 
repigmentation was signiﬁ  cantly shorter in the topical immu-
nomodulator group.51
In a prospective placebo-controlled right-left comparison 
study, Hartmann et al investigated the efﬁ  cacy and safety of 
0.1% tacrolimus ointment for up to 12 months in 30 adult 
patients with vitiligo, and tested the inﬂ  uence of additional 
occlusion. They concluded that 0.1% tacrolimus ointment 
proved an effective and safe treatment option for adult patients 
with vitiligo. Beyond the face and neck areas, repigmentation Clinical, Cosmetic and Investigational Dermatology 2009:2 20
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could be achieved only by additional occlusion (eg, household 
foil, hydrocolloid dressing or polyurethane foil).50
A recent randomized, double-blind, placebo-controlled 
study compared combination of 1% pimecrolimus with 
NB-UVB versus placebo with NB-UVB and concluded that, 
on the face, NB-UVB works better if combined with 1% 
pimecrolimus cream than used alone.52
Topical calcineurin inhibitors are effective in the treat-
ment of vitiligo, especially when the lesions are situated on 
the face.
Unlike topical corticosteroids, topical calcineurin inhibi-
tors do not cause skin atrophy. A noted side-effect was a 
burning sensation at the site of application. In 2005, the 
Pediatric Advisory Committee of the US FDA implemented 
a black box warning for tacrolimus and pimecrolimus due to 
the lack of long-term safety data and the potential risk of the 
development of malignancies. However, evidence of a causal 
relation to the development of skin cancer or lymphoma is 
still missing. More studies are needed to understand this 
risk.53,54
Pseudocatalase cream
One study showed that patients with vitiligo have low catalase 
levels in their epidermis in association with accumulation of 
hydrogen peroxide (H2O2). A topical pseudocatalase cream 
and calcium used twice daily with UVB therapy, twice weekly, 
resulted in repigmentation in the majority of cases in a case 
study with 33 patients after 2–4 months. However, it was not 
known whether the repigmentation was due to the UVB or 
the pseudocatalase.55 Sanclemente et al compared the effect 
of topical 0.05% betamethasone valerate versus catalase/
dismutase superoxide (C/DSO) and concluded that vitiligo 
repigmentation with topical C/DSO at 10 months is similar to 
repigmentation with topical 0.05% betamethasone valerate.18
More studies on the use of pseudocatalase cream in 
the treatment of vitiligo are necessary to prove its possible 
therapeutic effect.
Comparison
Recently, Lotti et al performed an open-label study compar-
ing the current non-surgical treatments for vitiligo (311-nm 
narrowband microphototherapy, 0.1% tacrolimus ointment 
twice a day, 1% pimecrolimus cream twice a day, 0.05% 
betamethasone dipropionate cream twice a day, 0.005% calci-
potriol ointment twice a day and 10% l-phenylalanine cream 
twice a day as a monotherapy or the NB-UVB therapy in com-
bination with the above mentioned local treatments). They 
concluded that when the single treatments are considered 
alone, 311-nm narrowband UVB microphototherapy and 
0.05% betamethasone dipropionate cream are the most 
effective treatments. In combination therapies, 0.05% 
betamethasone dipropionate cream plus 311-nm narrowband 
UVB microphototherapy gave the best repigmentation rate. 
In this study, the only side-effects registered were cutane-
ous atrophy with the corticosteroid cream, and stinging and 
burning with the topical immunomodulators.56
Surgical repigmentation therapy
Surgical repigmentation can be considered in stabilized viti-
ligo, if other repigmentation therapies fail. All surgical tech-
niques have the same basic principle: to transplant autologous 
melanocytes from pigmented donor skin to regions without 
melanocytes. However, patients need to be carefully selected 
as not every vitiligo patch is suitable for transplantation. Sur-
gical techniques may be considered in stable, non-progressive 
disease only (there is no consensus on the exact period of 
stability, various recommendations suggest stable vitiligo 
for 6 months to 2 years).57 Contraindications are a positive 
Koebner phenomenon and hypertrophic scars or keloids in 
the past. The site of transplantation is also important, as some 
areas such as joints, lips, eyelids, genitalia, cutaneous folds, 
the dorsum of hands and feet, ﬁ  ngers and toes, are difﬁ  cult 
to repigment.58
There are several methods for surgical repigmentation.
Autologous minipunchgrafting
The ﬁ  rst method is autologous minipunchgrafting were 
multiple punch biopsies are obtained from a normally pig-
mented donor site and implanted within achromic areas, 
separated from each other by 5 to 8 mm. To determine if this 
technique works for a speciﬁ  c patient, a test-graft is performed 
(3–5 minigrafts). If pigment has spread from the donor tissue 
after a period of time and no Koebner phenomenon exists at 
the donor site, the entire region is grafted. This procedure 
is useful for limited areas of vitiligo, but a cobblestone 
appearance, sinking pits, infection or scarring are potential 
side-effects.3,59 In 1988, Falabella treated 22 patients with 
localized vitiligo with autologous minigrafting and a 90% to 
100% repigmentation was achieved in 13 patients.60 Another 
study by Sarkar et al showed a repigmentation rate of 40% to 
60% in the majority of the treated patients who has segmental 
vitiligo.61 Boersma et al performed minigrafts in patients 
with stable vitiligo vulgaris (stable for 6 months). 14 out of 
36 lesions showed 80% to 99% repigmentation after 6 months. 
They state that repigmentation rates of more than 80% are 
generally not reached before 6 months after grafting.62Clinical, Cosmetic and Investigational Dermatology 2009:2 21
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Epidermal suction blister grafting
Another technique is epidermal suction blister grafting. Blisters 
are formed at donor and recipient sites with a suction machine 
or by freezing with liquid nitrogen for 20 to 25 seconds. The 
roof of the blister is removed from both sites and the donor 
graft is placed on top of the denuded recipient site. The grafts 
are held in place with bandages for 7 days. Repigmentation 
usually occurs in 1 to 2 weeks, and total repigmentation can 
occur within 1 to 3 months.3 Gupta et al compared epidermal 
suction blister grafting to punch skin grafting in 49 patients and 
reported a repigmentation rate of more than 75% in 67% of the 
lesions in the punch graft group and in 82% of the lesions in the 
epidermal suction blister group. This difference was not signiﬁ  -
cant. However, the latter technique gives cosmetically better 
results. 63 The overall success rate of epidermal suction blister 
grafting varies between 73% and 88% in different studies and is 
increased if the donor site is treated with PUVA therapy before 
the procedure. Epidermal grafting shows excellent cosmetic 
results and is an easy, inexpensive, safe and efﬁ  cient treatment, 
however it is a time consuming technique.59
Split-thickness grafting
In split-thickness skin grafting, the whole epidermis and a 
part of the upper papillary dermis is grafted at the donor site 
using a hand dermatome or shaving blade. Grafts are posi-
tioned on abraded recipient areas that have been prepared 
previously. The graft is secured with pressure and immobi-
lization. This technique has a success rate of 78% to 90%.59 
Ozdemir et al were the ﬁ  rst to compare 2 surgical techniques 
in a blinded matter (epidermal suction blister grafting versus 
split-thickness skin grafting). In their study, 25% of patients 
showed repigmentation with suction blister erosion with-
out grafting, 45% of patients showed repigmentation with 
suction blister grafting. Thin split-thickness grafting led to 
repigmentation in 90% of patients.64 Success rates depend on 
using a very thin graft to prevent additional cosmetic damage 
to both recipient and donor areas. Side-effects of this tech-
nique are stuck-on effects, persistent hyperpigmentation, 
milia, perigraft halo of depigmentation and scars on donor 
areas, and it is not suitable for vitiliginous lesions on the 
palms, soles, and skin folds. The beneﬁ  ts are the immediate 
results, the highest success mean rate and the ability to treat 
difﬁ  cult areas like eyelids, penis, vagina and lips.65,66
Transplantation of non-cultured epidermal 
cellsuspension
In 1992, Gauthier and Surleve-Bazeille described a technique 
in which non-cultured melanocytes were isolated from samples 
of skin of the hair scalp, then trypsinized and transplanted. 
The grafting method is carried out in two steps: ﬁ  rst, blisters 
are formed on the depigmented lesions by freezing with liquid 
nitrogen, then, each blister is injected with a suspension of 
epidermal cells (mainly keratinocytes and melanocytes). 
Repigmentation occurred within 25 to 30 days and they 
concluded that this technique is an effective and simple 
transplantation method.67 With this technique, large areas can 
be treated (5- to 10-fold the donor area). Disadvantages are 
a long-lasting erythema (up to 6 months) at the recipient site 
due to dermabrasion and the need for specialized laboratories 
with trained personnel.59
Van Geel et al performed the ﬁ  rst double-blind placebo-
controlled study on autologous transplanted epidermal 
cell suspensions for repigmenting vitiligo. To improve the 
viscosity and ﬁ  xation of the cellsuspension, they investi-
gated a modiﬁ  ed approach adding hyaluronic acid to the 
cellular grafting procedure. In this study, transplantation 
resulted in repigmentation of at least 70% of the treated 
area in the majority of patients. They could demonstrate that 
repigmentation was primarily caused by the transplanted 
melanocytes, as repigmentation at the placebo treated site 
was negligible.68
Mulekar performed a long-term follow-up study in 
142 patients treated with a non-cultured melanocyte–keratinocyte 
cell transplantation. More than half of the treated patients had 
a complete repigmentation that was fully retained for a 6-year 
follow-up period.69
Transplantation of in vitro-cultured epidermis
A shave biopsy of normally pigmented skin is taken. After 
separating the epidermis from the dermis, the cells are seeded 
in a medium that allows co-cultivation of melanocytes and 
keratinocytes. After 3 weeks a cultured sheet is obtained, 
released by treatment with dispase and attached to a gauze 
as support. The gauze (to which the epithelium adheres) is 
placed onto the recipient site after it is treated with derm-
abrasia.55 This technique has the advantage that a large area 
can be treated (10 fold the donor site). Studies have shown a 
good repigmentation in 33% to 54% of treated patients.59,70,71 
A side-effect of this technique can be hyperpigmentation, 
but this tends to disappear after a few months. Another 
disadvantage is failure of culture and the fact that it is an 
expensive procedure.
Transplantation of in vitro-cultured melanocytes
Here, melanocytes are obtained from shave biopsies and 
cultured in vitro with addition of growth factors and chemical Clinical, Cosmetic and Investigational Dermatology 2009:2 22
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Table 1 Conclusions on treatment for vitiligo
 Conclusion Remarks
Non-surgical treatments
Topical corticosteroids Effective for the treatment of localized 
vitiligo
Result of meta-analysis
Oral corticosteroids Have an adjunct value, not very effective 
by themselves
No placebo controlled studies have been 
performed for oral corticosteroids as a 
monotherapy
(P)UVA Broadband UVA alone may have a 
therapeutic value PUVA therapy is as 
effective as broadband UVB, but with 
more side-effects
UVA is not studied in RCTs
Broadband UVB Effective for the treatment for 
generalized vitiligo
Narrowband UVB As effective as broadband UVB, 
and sometimes even preferred 
over broadband UVB. Preferred for 
generalized vitiligo
Result of meta-analysis
Excimer laser Excimer laser is an effective and safe 
treatment for vitiligo and gives the best 
results if used on the face
Calcipotriol Contradicting results: some authors 
describe a beneﬁ  t but others do not
No placebo controlled studies have been 
performed for topical calcipotriol as a 
monotherapy
Topical immunomodulators As effective in repigmentation as topical 
corticosteroids
The effect is mainly restricted to the face 
and neck
Pseudocatalase cream May have an effect Few studies performed
Surgical treatments Few (comparative) studies performed
Autologous minipunchgrafting Success rates of 40%–99% (mean success 
rate: 57%) Only a small surface can be 
treated
Lower mean success rate than epidermal 
suction blister grafting and split-thickness 
skin grafting
Epidermal suction blister grafting Success rates of 73%–88% (mean success 
rate: 81%)
Only a small surface can be treated
Split-thickness skin grafting Success rates of 78%–90%
Transplantation of non-cultured epidermal 
cellsuspension
Success rates of 59%–70% (mean success 
rate: 63%) Suitable for larger areas
Transplantation of in vitro-cultured 
epidermis
Success rates of 33%–54%
Transplantation of in vitro-cultured 
melanocytes
Success rates of 22%–72%
Depigmentation therapy
Monobenzylether of hydroquinone Effective as a depigmentation therapy Few studies performed
Mequinol Effective as a depigmentation therapy Few studies performed
Complementary therapies
L-phenylalanine May be used as adjuvant to phototherapy Few studies performed
Ginkgo biloba May be effective as monotherapy Only shown in one study
Polypodium leucomotos Can improve narrowband UVB-induced 
repigmentation
Few studies performed
Antioxidants Can improve the clinical effectiveness 
of narrowband UVB
Few studies performed
Abbreviations: PUVA, psoralen ultraviolet-A therapy; RCT, randomized controlled trial.Clinical, Cosmetic and Investigational Dermatology 2009:2 23
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media. The suspension is then transplanted on abrased 
recipient areas. Success rates vary between 22% and 72%. 
Disadvantages are that it is a time consuming technique 
and that there are only a few trials published that study this 
technique.57 In 2004, Chen et al performed an analysis of 
120 patients with vitiligo who were treated with autologous 
cultured pure melanocyte suspension combined with carbon 
dioxide laser abrasion. They concluded that this technique is 
an effective treatment for patients with stable vitiligo who 
fail to respond to medical treatments, especially for those 
with stable localized vitiligo.72
As there are no uniform and acceptable criteria for the 
evaluation of the outcome after surgical repigmentation, it 
is difﬁ  cult to compare the results of different studies on dif-
ferent transplantation methods.
In 1998, Njoo et al performed a systematic review of the 
effectiveness, safety, and applicability of autologous transplanta-
tion methods in vitiligo. Recently developed techniques using 
noncultured epidermal cellsuspension were not included in the 
review. Split-thickness grafting and epidermal blister grafting 
were the most effective and safest methods in this review. Mini-
grafting showed a relatively lower success rate, which could be 
explained by variations in the size of pigment spread of the punch 
grafts. They state that postoperative PUVA therapy or exposition 
to sunlight may improve the repigmentation grade in minigraft-
ing.73 However, as no randomized controlled trials were included 
in the review, results should be interpreted with caution.
Depigmentation therapy
Depigmentation with monobenzylether of hydroquinone can 
be considered if vitiligo affects more than 60% to 80% of the 
face or body. The major side-effect is contact or irritant con-
tact dermatitis. Only a few studies (no randomized controlled 
trials) with hydroquinone for vitiligo have been performed. 
In a retrospective study of 18 vitiligo patients who used 20% 
monobenzylether of hydroquinone as a depigmenting agent, 
8 achieved complete depigmentation after 10 months of use 
and 3 achieved dramatic but no complete depigmentation.74 
In 1996, Oakley described a rapid repigmentation after 
depigmentation with monobenzylether of hydroquinone, the 
mechanism was unknown.75
4-methoxyphenol (4-MP) or mequinol is another phe-
nol derivate and has similar melanocytotoxic properties as 
monobenzylether of hydroquinone. Njoo et al performed a 
retrospective study on depigmentation therapy in 16 patients 
and concluded that depigmentation therapy using a 4-MP 
cream and/or Q-switched ruby laser therapy can be an 
effective and safe method to remove residual pigment in 
patients with vitiligo universalis.76 However, because there 
are no randomized controlled trials performed, results should 
be considered with caution.
Complementary therapies
Just recently, Szczurko and Boon performed a comprehen-
sive review of literature on different natural health products 
that may have an effect on vitiligo. The most commonly 
studied product was L-phenylalanine, not in monotherapy 
but in combination with phototherapy or other products. 
Although it was not possible to pool the collected data, the 
overall outcome was that there is moderate evidence for 
efﬁ  cacy of L-phenylalanine as adjuvant to phototherapy. 
There was no convincing evidence that vitamins have a 
place in vitiligo treatment.77 Ginkgo biloba also seems to be 
promising as monotherapy for vitiligo in a double-blind, pla-
cebo-controlled trial, performed by Parsad et al but more and 
controlled studies are necessary to conﬁ  rm this effect.78
In 2007, Middelkamp-Hup et al performed a randomized 
double-blind placebo-controlled study to determine if polypo-
dium leucotomos, an antioxidative and immunomodulatory 
plant extract, improves narrowband UVB-induced repigmen-
tation. There was a trend towards an increased repigmentation 
of head and neck (not other body areas) in the group that was 
treated with the combination of polypodium leucomotos and 
UVB. This effect was more pronounced in patients with light 
skin types (type II and III).79 Another study by Dell’Anna et al 
evaluated the combination treatment of antioxidants (contain-
ing alpha-lipoid acid, vitamins C and E and polyunsaturated 
fatty acids) and narrowband UVB in a double-blind placebo 
controlled trial and concluded that the antioxidants sig-
niﬁ  cantly improved the clinical effectiveness of narrowband 
UVB, reducing vitiligo-associated oxidative stress.80
Conclusion
Many studies have been performed to determine which treat-
ment is the best for vitiligo (table 1). Since there is no consen-
sus on the pathogenesis of vitiligo, a treatment to completely 
cure vitiligo does not exist. More randomized controlled trials 
on the treatment of vitiligo are necessary.
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